Wolfgang Miesbach: Rebalancing Agents in Haemophilia Are Not “Set and Forget” – Key Insights from WFH 2026
Wolfgang Miesbach, Professor of Medicine at Frankfurt University Hospital, shared posts on LinkedIn, highlighting key insights from the World Federation of Hemophilia (WFH) 2026 Congress։
”Rebalancing agents are not ‘set and forget’
Excellent presentation today by Alok Srivastava at the Sanofi industry symposium during WFH Congress Kuala Lumpur on rebalancing agents in haemophilia – showing how different targets (TFPI leads to concizumab / marstacimab; AT leads to fitusiran), loading doses and maintenance intervals (QD / QW / Q2M) demand truly individualised dosing strategies.
- Traditional assays (PT / aPTT) largely unaffected
- PK/PD (where available) help to fine‑tune dose / frequency to maintain target range
- Global assays (TGA / TEG / ROTEM) could be useful in selected settings (e.g. peri‑operative management)
- All dosing decisions embedded in shared decision‑making, patient goals, comorbidities, thrombosis risk
A timely reminder that optimising dose and monitoring is now central to safe and effective haemostatic rebalancing.”
”In the rebalancing era, proactive, protocol‑driven management of any breakthrough bleed has become a fourth pillar of haemophilia care – alongside prophylaxis, monitoring and shared decision‑making.
Interesting summary of treatment recommendations for breakthrough bleeds under rebalancing agents, presented by Alok Srivastava at the Sanofi industry symposium during the WFH Congress in Kuala Lumpur.
- Patient population: haemophilia A/B, ± inhibitors
- Product choice: FVIII/FIX (standard or EHL), aPCC, rFVIIa
- Principle: use the lowest effective dose
- Interval before repeat dosing: typically 24 h vs 5–7 d, depending on product
- Antifibrinolytics: allowed, used with caution or avoided with certain agents.”
Other posts featuring Wolfgang Miesbach on Hemostasis Today.
-
Jun 8, 2026, 03:05Shamsunisha Yusuff: Iron Down, Platelets Up in a Young CBC ?
-
Jun 8, 2026, 03:03Samwel Mikaye: D-Dimer – A Marker of Blood Clot Breakdown
-
Jun 8, 2026, 02:59Vinita Madhuri: Our Engagement, A Lifeline for Thalassemia Patients
-
Jun 7, 2026, 22:11Lucia Härtel: Exercise, IL-10 Signaling, and Post-Stroke Brain Plasticity
-
Jun 7, 2026, 19:35Ashish Pemawat: Is the 4.5-Hour Thrombolysis Window Becoming Less Relevant?
-
Jun 7, 2026, 18:25Nita Radhakrishnan: Every Child Cured Is a Reminder of What Can Be Achieved When We Work Together
-
Jun 7, 2026, 18:24Yvette Fairfax: Wiskott-Aldrich Gene Therapy Changes Immunity, but Affordability May Determine Survival
-
Jun 7, 2026, 18:21Gulab Makwana: Complete Guide to Clotting Factors – Understanding the Coagulation System
-
Jun 7, 2026, 18:15Chuhan Dong: Presenting My Research on Antibody-Mediated RBC Clearance at Canadian Blood Services